Further Investment In Three New Australian COVID-19 Vaccine Research Projects
Date posted 22 September 2020 Release date 20 September 2020 The Morrison Government will invest almost $6 million in additional funding from the Medical Research Future Fund’s (MRFF) Coronavirus Research Response to support research and development of three…
A new discovery in regenerative medicine
Date posted 22 September 2020 Release date 17 September 2020 An international collaboration involving Monash University and Duke-NUS researchers have made an unexpected world-first stem cell discovery that may lead to new treatments for placenta complications during pregnancy.…
AdAlta and GE Healthcare collaboration progresses to next stage
Date posted 22 September 2020 Release date 20 September 2020 AdAlta Limited, a clinical stage biopharmaceutical discovery and development company using i-body technology to address challenging drug targets, is pleased to announce the extension of its collaboration with…
UniMelb tool uses fat in bone and muscle to diagnose disease, predict falls and fractures
Date posted 22 September 2020 Release date 17 September 2020 Doctors will soon be able to use fat to diagnose musculoskeletal disease within seconds and predict the risk of falls and fractures in older people, thanks to a…
Planet Innovation and Lumos Diagnostics pick up top Medical Design and Engineering Awards for rapid diagnostic development platform
15 September 2020 Planet Innovation and Lumos Diagnostics have won two awards at the 2020 Good Design Awards, including a Good Design Award Gold accolade for Lumos’s Leelu Reader. The annual Good Design Awards is Australia’s oldest and most…
Results of Cynata’s World-First Clinical Trial of iPSC-derived CYP-001 in GvHD Accepted for Publication in Nature Medicine
15 September 2020 Release date 14 September 2020 Cynata Therapeutics Limited, a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce that a paper describing the Phase 1 clinical trial of CYP-001 in patients with graft…
Starpharma’s SPL7013 COVID-19 nasal spray virucidal against SARS-CoV-2
15 September 2020 New data generated at Scripps Research Institute in the US shows that Starpharma’s antiviral nasal spray active (SPL7013) is virucidal, inactivating more than 99.9% of SARS-CoV-2, the virus that causes COVID-19 Potent antiviral activity of…
Opening eyes to a frontier in vision restoration
15 September 2020 Release date 14 September 2020 A world-first device to restore vision to the blind is being prepared for human clinical trials in Melbourne. Additional funding can help researchers establish an implantable device manufacturing facility to…
Nucleus Network Begins Clinical Trial of COVID-19 Antibody Treatment
15 September 2020 Release date 11 September 2020 Australia’s largest Phase 1 clinical trials specialist, Nucleus Network, has this week started the first human trials of a potential COVID-19 treatment developed by Singlomics (Beijing DanXu) Biopharmaceuticals and licensed…
University accelerates the process of 3D printed nasal swabs for COVID-19 testing
15 September 2020 Release date 11 September 2020 The University of Melbourne has brought together industry partners and researchers for the development of an Australian-first; locally manufactured 3D printed nasal swab for coronavirus (COVID-19) testing. 3DMEDiTECH, a partner…
Positive results flow continues for Dimerix’s DMX-200 kidney disease therapy candidate
14 September 2020 In what has been a steadily positive research progression so far, Melbourne-based clinical-stage biopharmaceutical company Dimerix has reported a continuation of strong clinical trial results for its drug candidate DMX-200, which is aimed at a…
Medtronic Study Finds Opioid-Induced Respiratory Depression in the Hospital More Common and Costly
14 September 2020 Release date 10 September 2020 PRODIGY Study Provides First Validated Risk Prediction Tool to Guide Continuous Monitoring for Opioid-Induced Respiratory Depression (OIRD) OIRD Occurred in 46% of Patients Studied Patients with Respiratory Depression Are 37%…
